(Q46116817)

19 December 2017

title

Clinical guidelines for overactive bladder (English)

1 reference

19 December 2017

9

Yasuhiko Igawa

1 reference

19 December 2017

Yukio Homma

5

object named as

Yukio Homma

1 reference

19 December 2017

author name string

Osamu Yamaguchi

1

1 reference

19 December 2017

Osamu Nishizawa

2

1 reference

19 December 2017

Masayuki Takeda

3

1 reference

19 December 2017

Osamu Yokoyama

4

1 reference

19 December 2017

Hidehiro Kakizaki

6

1 reference

19 December 2017

Kenji Obara

7

1 reference

19 December 2017

Momokazu Gotoh

8

1 reference

19 December 2017

Naarihito Seki

10

1 reference

19 December 2017

Masaki Yoshida

11

1 reference

19 December 2017

Neurogenic Bladder Society

12

1 reference

19 December 2017

publication date

1 February 2009

1 reference

19 December 2017

International Journal of Urology

published in

1 reference

19 December 2017

volume

16

1 reference

19 December 2017

issue

2

1 reference

19 December 2017

page(s)

126-142

1 reference

19 December 2017

The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society.

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02177.X

Overactive bladder symptoms: do we need urodynamics?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02177.X

Urodynamic classification of patients with symptoms of overactive bladder

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02177.X

Clinical efficacy and tolerability of extended‐release tolterodine and immediate‐release oxybutynin in Japanese and Korean patients with an overactive bladder: a randomized, placebo‐controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02177.X

Effectiveness of anticholinergic drugs compared with placebo in the treatment of overactive bladder: systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02177.X

Reduced perception of urgency in treatment of overactive bladder with extended-release tolterodine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02177.X

Voiding and incontinence frequencies: variability of diary data and required diary length

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02177.X

Measurement characteristics of a voiding diary for use by men and women with overactive bladder

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02177.X

Voiding diary for the evaluation of urinary incontinence and lower urinary tract symptoms: prospective assessment of patient compliance and burden.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02177.X

Fluid intake and urinary incontinence in older community-dwelling women.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02177.X

Comparative efficacy of behavioral interventions in the management of female urinary incontinence. Continence Program for Women Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02177.X

Urodynamic changes associated with behavioral and drug treatment of urge incontinence in older women

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02177.X

Behavioral training with and without biofeedback in the treatment of urge incontinence in older women: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02177.X

The Effects of Patterned Urge-Response Toileting (PURT) on Urinary Incontinence among Nursing Home Residents

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02177.X

Effects of tolterodine, trospium chloride, and oxybutynin on the central nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02177.X

Identification of medications that cause cognitive impairment in older people: the case of oxybutynin chloride

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02177.X

Comparative efficacy and safety of transdermal oxybutynin and oral tolterodine versus placebo in previously treated patients with urge and mixed urinary incontinence

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02177.X

A placebo-controlled, multicentre study comparing the tolerability and efficacy of propiverine and oxybutynin in patients with urgency and urge incontinence.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02177.X

Long-term safety, tolerability and efficacy of extended-release tolterodine in the treatment of overactive bladder in Japanese patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02177.X

Treatment of overactive bladder with once-daily extended-release tolterodine or oxybutynin: the antimuscarinic clinical effectiveness trial (ACET).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02177.X

Efficacy, safety, and tolerability of extended-release once-daily tolterodine treatment for overactive bladder in older versus younger patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02177.X

Tolterodine extended release improves patient-reported outcomes in overactive bladder: results from the IMPACT trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02177.X

Efficacy of antimuscarinic therapy for overactive bladder with varying degrees of incontinence severity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02177.X

Combination treatment with an alpha-blocker plus an anticholinergic for bladder outlet obstruction: a prospective, randomized, controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02177.X

A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02177.X

Randomized, double-blind placebo controlled trial of the once daily antimuscarinic agent solifenacin succinate in patients with overactive bladder

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02177.X

Solifenacin significantly improves all symptoms of overactive bladder syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02177.X

Improved quality of life in patients with overactive bladder symptoms treated with solifenacin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02177.X

Efficacy and tolerability of solifenacin in elderly subjects with overactive bladder syndrome: a pooled analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02177.X

Efficacy of solifenacin in patients with severe symptoms of overactive bladder: a pooled analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02177.X

Solifenacin is effective for the treatment of OAB dry patients: a pooled analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02177.X

Long-term open-label solifenacin treatment associated with persistence with therapy in patients with overactive bladder syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02177.X

Symptom bother and health-related quality of life outcomes following solifenacin treatment for overactive bladder: the VESIcare Open-Label Trial (VOLT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02177.X

Solifenacin for overactive bladder with incontinence: symptom bother and health-related quality of life outcomes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02177.X

Cardiovascular safety and overall tolerability of solifenacin in routine clinical use: a 12-week, open-label, post-marketing surveillance study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02177.X

Double-blind study of imipramine and placebo for incontinence due to bladder instability

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02177.X

Clinical options for imipramine in the management of urinary incontinence

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02177.X

Vanilloid receptor and detrusor instability.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02177.X

Mechanisms underlying the recovery of urinary bladder function following spinal cord injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02177.X

Intravesical capsaicin for neurogenic bladder dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02177.X

Desensitization of bladder sensory fibers by intravesical resiniferatoxin, a capsaicin analog: long-term results for the treatment of detrusor hyperreflexia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02177.X

Effectiveness of intravesical resiniferatoxin for anticholinergic treatment refractory detrusor overactivity due to nonspinal cord lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02177.X

Intravesical capsaicin versus resiniferatoxin for the treatment of detrusor hyperreflexia in spinal cord injured patients: a double-blind, randomized, controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02177.X

Role of C afferent fibers and monitoring of intravesical resiniferatoxin therapy for patients with idiopathic detrusor overactivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02177.X

Botulinum a toxin and detrusor sphincter dyssynergia: a double-blind lidocaine-controlled study in 13 patients with spinal cord disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02177.X

Intravesical resiniferatoxin versus botulinum-A toxin injections for neurogenic detrusor overactivity: a prospective randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02177.X

Darifenacin, an M3 selective receptor antagonist, is an effective and well-tolerated once-daily treatment for overactive bladder

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02177.X

Urodynamic effects of various treatment modalities for benign prostatic hyperplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02177.X

Overactive bladder in men: special considerations for evaluation and management.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02177.X

A meta-analysis on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02177.X

Urodynamic and clinical effects of terazosin therapy in symptomatic patients with and without bladder outlet obstruction: a stratified analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02177.X

Doxazosin in men with lower urinary tract symptoms: urodynamic evaluation at 15 months

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02177.X

Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02177.X

Electrical stimulation in overactive bladder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02177.X

10.1111/J.1442-2042.2008.02177.X

21 January 2018

Identifiers

DOI

1 reference

19 December 2017

PubMed ID

19228224

1 reference

19 December 2017